Literature DB >> 21620725

The effect of fluid intake on chronic kidney transplant failure: a pilot study.

Laurene Magpantay1, Farzad Ziai, Rainer Oberbauer, Martin Haas.   

Abstract

OBJECTIVE: Transplant recipients are generally instructed to increase their daily fluid intake so as to preserve kidney function. However, studies supporting this hypothesis are lacking.
SETTING: Prospective, randomized study at a tertiary care university hospital. PATIENTS: Patients with chronic kidney transplant failure. INTERVENTION: Assignment to normal fluid intake (NFI: 2 L/day) or high fluid intake (HFI: 4 L/day) for 12 months. MAIN OUTCOME MEASURE: The effect of fluid intake on the decrease in estimated glomerular filtration rate (eGFR) was estimated by a mixed-effects general linear model. The analysis was adjusted for the observation period, age, intake of angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers, diuretics, and transplant duration.
RESULTS: A total of 33 patients were randomized to NFI and 29 to HFI. After 12 months, the mean eGFR had decreased to a similar extent in both groups (NFI: 44 ± 9 mL/min vs. 41 ± 9 mL/min; HFI: 46 ± 15 mL/min vs. 44 ± 15 mL/min). In the multivariate analysis, only the observation period had a significant effect on the decrease in eGFR. Randomization to NFI or HFI nor any other variable was associated with kidney function. The association between urine volume and urine osmolality was lost after 12 months.
CONCLUSIONS: Recommendation of higher fluid intake does not seem to improve chronic kidney transplant failure. However, the lack of association between urine osmolality and reported urine volume at a later stage implies a loss of adherence to fluid intake over time.
Copyright © 2011 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21620725     DOI: 10.1053/j.jrn.2011.01.020

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  7 in total

1.  Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Authors:  Olivier Devuyst; Arlene B Chapman; Ron T Gansevoort; Eiji Higashihara; Ronald D Perrone; Vicente E Torres; Jaime D Blais; Wen Zhou; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2016-12-05       Impact factor: 10.121

Review 2.  Effects of dietary interventions on incidence and progression of CKD.

Authors:  Nishank Jain; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2014-10-21       Impact factor: 28.314

3.  Daily fluid intake and outcomes in kidney recipients: post hoc analysis from the randomized ABCAN trial.

Authors:  M Weber; D Berglund; S Reule; S Jackson; A J Matas; H N Ibrahim
Journal:  Clin Transplant       Date:  2015-03       Impact factor: 2.863

4.  Thinking Outside the Box: Novel Kidney Protective Strategies in Kidney Transplantation.

Authors:  Hassan N Ibrahim; Dina N Murad; Greg A Knoll
Journal:  Clin J Am Soc Nephrol       Date:  2021-03-23       Impact factor: 8.237

5.  Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.

Authors:  Niek F Casteleijn; Jaime D Blais; Arlene B Chapman; Frank S Czerwiec; Olivier Devuyst; Eiji Higashihara; Anna M Leliveld; John Ouyang; Ronald D Perrone; Vicente E Torres; Ron T Gansevoort
Journal:  Am J Kidney Dis       Date:  2016-11-14       Impact factor: 8.860

Review 6.  High Water Intake and Progression of Chronic Kidney Diseases.

Authors:  Hoon Young Choi; Hyeong Cheon Park; Sung Kyu Ha
Journal:  Electrolyte Blood Press       Date:  2015-12-30

7.  Instructions for kidney recipients and donors (In English for medical providers and in Arabic for patients and donors).

Authors:  Ziad Arabi; Basmeh Ghalib; Ibrahim Asmari; Mohammed Gafar; Syed Alam; Mohamad Abdulgadir; Ala AlShareef; Awatif Rashidi; Mohammed Alruwaymi; Abdulrahman Altheaby
Journal:  Avicenna J Med       Date:  2020-01-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.